Drug Price Trends for INSULIN GLARGINE-YFGN U100 PEN

Average Pharmacy Cost for INSULIN GLARGINE-YFGN U100 PEN

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
INSULIN GLARGINE-YFGN U100 PEN	49502-0394-75	5.93498	ML	2025-03-19
INSULIN GLARGINE-YFGN U100 PEN	83257-0015-32	5.93498	ML	2025-03-19
INSULIN GLARGINE-YFGN U100 PEN	49502-0394-75	5.93364	ML	2025-02-19
INSULIN GLARGINE-YFGN U100 PEN	83257-0015-32	5.93364	ML	2025-02-19

Insulin Glargine-YFGN U100 Pen: Market Analysis and Price Projections

Market Overview

The insulin glargine market, which includes products like the insulin glargine-yfgn U100 pen, is experiencing significant growth driven by the increasing prevalence of diabetes globally. Here are some key points to consider:

• Global Market Size: The global insulin glargine market was valued at USD 1.29 billion in 2022 and is projected to reach USD 2.2 billion by 2031, growing at a CAGR of 6.11% during the forecast period (2023-2031)[1][3].
• Regional Dominance: North America is the largest market shareholder, primarily due to the high prevalence of diabetes in the region, especially in the United States. The U.S. diabetes population has risen to 25.81 million as of 2020, with Type 2 diabetes increasing at an alarming rate[1][3].

Market Drivers

Several factors are driving the growth of the insulin glargine market:

• Increasing Diabetes Prevalence: The global rise in diabetes cases, particularly Type 2 diabetes, is a major driver. Sedentary lifestyles and unhealthy dietary habits contribute significantly to this trend[1][3].
• Technological Advancements: The development of new insulin delivery devices, such as insulin pens, has improved patient compliance and accuracy in insulin administration. Smart insulin pens that track dosage and timing are further enhancing market growth[4].
• Regulatory Approvals: Frequent approvals and launches of novel products, including biosimilar insulin products like Semglee (insulin glargine-yfgn), are expanding market opportunities[1].

Product Specifics: Insulin Glargine-YFGN U100 Pen

Product Description

Insulin glargine-yfgn, marketed under the brand name Semglee, is a long-acting insulin analog used for the treatment of Type 1 and Type 2 diabetes. It is available in prefilled insulin pens and vials for subcutaneous injection[5].

Pricing

The cost of insulin glargine-yfgn without insurance can be substantial:

• Semglee Pricing: A box of 5 pens of 3 mL containing 100 units/mL of Semglee can cost over $550 without insurance. The list price per 3 mL pen is around $110[5].
• Generic Alternatives: The unbranded version of insulin glargine-yfgn can offer significant savings, with prices around $100 per box of 5 pens[5].

Cost-Saving Options

Several strategies can help make insulin glargine-yfgn more affordable:

• Discount Cards: Using discount cards, such as those from SingleCare, can reduce the cost of Semglee by up to 80%, bringing the price down to around $425 per box[5].
• Generic Formulations: Opting for the unbranded insulin glargine-yfgn can lower costs further, making it a more accessible option for patients without insurance[5].
• Pharmacy Price Comparison: Shopping around different pharmacies can also help in finding better prices[5].

Market Challenges

Despite the growth, the insulin glargine market faces several challenges:

• High Product Costs: The high cost of insulin glargine products is a significant barrier, especially for patients without insurance. This can lead to affordability issues and impact market growth[1][5].
• Regulatory Hurdles: Strict policies and regulations for product approval can slow down market growth. The availability of substitutes also poses a challenge[1].

Technological and Market Trends

Insulin Delivery Devices

The market is seeing a shift towards more convenient and accurate insulin delivery devices:

• Insulin Pens: Insulin pens, including smart pens, are gaining popularity due to their ease of use, accuracy, and less painful injections. These devices are particularly beneficial for inpatient care and elderly patients[4].
• Smart Insulin Pens: The development of smart insulin pens that can track dosage and timing is further enhancing patient compliance and control over their condition[4].

Regional Growth

• North America: This region continues to dominate the market due to the high prevalence of diabetes and advanced healthcare systems. However, the Asia Pacific region is expected to grow at the fastest CAGR, driven by increasing awareness and technological advancements[1][3][4].

Expert Insights

Industry experts highlight the importance of addressing the systemic issues surrounding insulin pricing and accessibility:

"The price of insulin illustrates a systemic problem with how drugs are priced compared to other commodities. This is a stark and troubling example of the surging cost of prescription drugs in the United States"[1].

Statistics and Data

• Market Growth: The global insulin glargine market is expected to grow at a CAGR of 6.11% from 2023 to 2031[1].
• Diabetes Prevalence: The total diabetes population in the United States has increased to 25.81 million as of 2020, with Type 2 diabetes soaring at an alarming rate[1].
• Healthcare Costs: Patients with diabetes incur more healthcare expenses than non-diabetic individuals, with a 300% increased risk of hospitalization[3].

Key Takeaways

• The insulin glargine market, including products like the insulin glargine-yfgn U100 pen, is growing due to the increasing prevalence of diabetes.
• North America is the largest market shareholder, driven by the high prevalence of diabetes in the region.
• Technological advancements in insulin delivery devices and regulatory approvals are key drivers of market growth.
• High product costs and regulatory hurdles are significant challenges.
• Cost-saving options such as discount cards and generic formulations can make insulin glargine-yfgn more affordable.

FAQs

What is the projected market size of the global insulin glargine market by 2031?

The global insulin glargine market is estimated to reach USD 2.2 billion by 2031, growing at a CAGR of 6.11% during the forecast period (2023-2031)[1].

How much does Semglee (insulin glargine-yfgn) cost without insurance?

A box of 5 pens of 3 mL containing 100 units/mL of Semglee can cost over $550 without insurance, with the list price per 3 mL pen being around $110[5].

What are some cost-saving options for insulin glargine-yfgn?

Using discount cards, opting for generic formulations, and comparing pharmacy prices can help reduce the cost of insulin glargine-yfgn[5].

Which region is expected to grow the fastest in the insulin glargine market?

The Asia Pacific region is projected to grow at the fastest CAGR, driven by increasing awareness and technological advancements[3][4].

How do smart insulin pens contribute to market growth?

Smart insulin pens enhance patient compliance and control over their condition by tracking dosage and timing, making them a preferred option for managing diabetes[4].

What are the main challenges facing the insulin glargine market?

High product costs and regulatory hurdles are significant challenges impacting the growth of the insulin glargine market[1][5].

Sources

1. Straits Research: "Insulin Glargine Market Size to Reach 2200 Million by 2031"
2. Drugs.com: "Insulin glargine Prices, Coupons, Copay Cards & Patient Assistance"
3. Mordor Intelligence: "Insulin Glargine Market - Size & Share"
4. Grand View Research: "Insulin Pens Market Size, Share And Growth Report, 2030"
5. SingleCare: "How much is Semglee (insulin glargine-yfgn) without insurance?"